AR042920A1 - Liberacion controlada de agentes muy solubles - Google Patents

Liberacion controlada de agentes muy solubles

Info

Publication number
AR042920A1
AR042920A1 ARP040100205A ARP040100205A AR042920A1 AR 042920 A1 AR042920 A1 AR 042920A1 AR P040100205 A ARP040100205 A AR P040100205A AR P040100205 A ARP040100205 A AR P040100205A AR 042920 A1 AR042920 A1 AR 042920A1
Authority
AR
Argentina
Prior art keywords
hydrochloride
agent
sustained release
formulation
inner core
Prior art date
Application number
ARP040100205A
Other languages
English (en)
Original Assignee
Control Delivery Sys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Control Delivery Sys Inc filed Critical Control Delivery Sys Inc
Publication of AR042920A1 publication Critical patent/AR042920A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0092—Hollow drug-filled fibres, tubes of the core-shell type, coated fibres, coated rods, microtubules or nanotubes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/28—Materials for coating prostheses
    • A61L27/34—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08—Materials for coatings
    • A61L31/10—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/21—Acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/432—Inhibitors, antagonists
    • A61L2300/436—Inhibitors, antagonists of receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/602—Type of release, e.g. controlled, sustained, slow

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Surgery (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Formulaciones de liberación sostenida para la administración sistémica de fármacos u otros agentes terapéuticos que son muy solubles en agua. Métodos de administración de los agentes y los dispositivos útiles para la administración. En particular, formulaciones de liberación sostenida para el tratamiento del glaucoma, incluyendo métodos y dispositivos adecuados para la administración de las formulaciones. Reivindicación 1: Una formulación de liberación sostenida, que comprende: un núcleo interior que comprende una cantidad terapéuticamente eficaz de al menos un agente, donde el al menos un agente es opcionalmente una base libre o un ácido protonado, dicho al menos un agente tiene una solubilidad en solución acuosa de aproximadamente 10 mg/ml o menor; y un revestimiento polimérico exterior que cubre al menos una porción del núcleo interior. Reivindicación 6: La formulación de la reivindicación 5, en la cual el revestimiento polimérico no-bioerosionable se selecciona de poliuretano, polisilicona, poli(etileno-co-vinil acetato), alcohol polivinílico y derivados y copolímeros de los mismos. Reivindicación 10: La formulación de la reivindicación 9, en la cual la matriz polimérica bioerosionable se selecciona de polianhidrido, ácido poliláctico, ácido poliglicólico, poliortoéster, polialquilcianoacrilato y derivados y copolímeros de los mismos. Reivindicación 17: La formulación de la reivindicación 1 0 2, en la cual el al menos un agente y el revestimiento polimérico exterior son co-extrudados. Reivindicación: 23 La formulación de la reivindicación 1 o 2, en la cual el al menos un agente en su forma salina se selecciona de maleato de timolol, clorhidrato de betaxolol, clorhidrato de metformina, clorhidrato de vancomicina, captopril, lactobionato de eritromicina, clorhidrato de ranitidina, clorhidrato de sertralina, clorhidrato de tramadol, clorhidrato de ticlopidina, bitartrato de nicotina, clorhidrato de oxibutinina, clorhidrato de diltiazem, propanolol, amoxicilina, cefuroxina axetil, cefactor, clindamicina, azitromicina, ceftazidina, clorhidrato de dorzolamida, acetazolamida, brinzolamida, metazolamida y diclorfenamida. Reivindicación 24: Un dispositivo de administración de fármaco que comprende: un sustrato que tiene una superficie, y una formulación de liberación sostenida adherida a la superficie, comprendiendo la formulación de liberación sostenida un núcleo interior que tiene una cantidad terapéuticamente eficaz de al menos un agente, en la cual el al menos un agente es una base libre o un ácido protonado, y tiene una solubilidad en agua que es aproximadamente 10 mg/ml o menor, y un revestimiento polimérico exterior que cubre al menos una porción del núcleo interior. Reivindicación 65: Un método para tratar el glaucoma que comprende: proveer una cantidad terapéuticamente eficaz de una base libre de una sal muy soluble en agua de al menos un agente que es eficaz en el tratamiento del glaucoma, conformar una formulación de liberación sostenida que tiene un núcleo interior que comprende la base libre, donde el núcleo interior está cubierto al menos en parte por un revestimiento polimérico exterior; proveer la formulación de liberación sostenida en un vehículo farmacéuticamente aceptable; y administrar la formulación de liberación sostenida a un paciente que padece glaucoma.
ARP040100205A 2003-01-24 2004-01-23 Liberacion controlada de agentes muy solubles AR042920A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US44249903P 2003-01-24 2003-01-24

Publications (1)

Publication Number Publication Date
AR042920A1 true AR042920A1 (es) 2005-07-06

Family

ID=32825229

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040100205A AR042920A1 (es) 2003-01-24 2004-01-23 Liberacion controlada de agentes muy solubles

Country Status (12)

Country Link
US (1) US20040175426A1 (es)
EP (1) EP1592411A2 (es)
JP (1) JP2006516621A (es)
KR (1) KR20050123091A (es)
CN (3) CN1741792A (es)
AR (1) AR042920A1 (es)
AU (1) AU2004207523A1 (es)
BR (1) BRPI0406858A (es)
CA (1) CA2513884A1 (es)
MX (1) MXPA05007717A (es)
TW (1) TW200509998A (es)
WO (1) WO2004066983A2 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004251457B2 (en) * 2003-06-26 2010-09-23 Mediolanum Pharmaceuticals Ltd. Subcutaneous implants having limited initial release of the active principle and subsequent linearly varying extended release thereof
TWI357815B (en) * 2003-06-27 2012-02-11 Euro Celtique Sa Multiparticulates
US20070129402A1 (en) * 2004-12-27 2007-06-07 Eisai Research Institute Sustained release formulations
US20060246003A1 (en) * 2004-12-27 2006-11-02 Eisai Co. Ltd. Composition containing anti-dementia drug
JP2008525313A (ja) 2004-12-27 2008-07-17 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗痴呆薬の安定化方法
US20090023778A1 (en) * 2005-04-28 2009-01-22 Eisai R&D Management Co., Ltd. Composition Containing Anti-Dementia Drug
WO2007008752A2 (en) * 2005-07-07 2007-01-18 Farnam Companies, Inc. Sustained release pharmaceutical compositions for highly water soluble drugs
WO2008042227A1 (en) * 2006-09-28 2008-04-10 Med Institute, Inc. Medical device including an anesthetic and method of preparation thereof
WO2008039995A2 (en) * 2006-09-28 2008-04-03 Vance Products Incorporated, D/Ba Cook Urological Incorporated Medical device including a bioactive in a non-ionic and an ionic form and methods of preparation thereof
UY30883A1 (es) 2007-01-31 2008-05-31 Alcon Res Tapones punctales y metodos de liberacion de agentes terapeuticos
US8232531B2 (en) * 2007-03-29 2012-07-31 Varian Medical Systems, Inc. Corrosion barrier layer for photoconductive X-ray imagers
CN101053680B (zh) * 2007-05-23 2010-06-16 刘红玲 防治后发障形成的具抗增殖药涂层的人工晶体
CN104856782B (zh) * 2007-09-07 2017-09-12 马缇医疗股份有限公司 泪腺植入物及相关方法
FR2926467B1 (fr) * 2008-01-23 2011-01-21 Univ Lille Sciences Tech Prothese vasculaire impermeable et procede de preparation de ladite prothese
JP5641483B2 (ja) 2009-08-18 2014-12-17 国立大学法人東北大学 持続性ドラッグデリバリーシステム
KR20130086131A (ko) * 2010-04-06 2013-07-31 알러간, 인코포레이티드 전방내 약물 송달을 위한 서-방출 저장소 임플란트
CA3023364A1 (en) 2016-05-12 2017-11-16 Merck Sharp & Dohme Corp. Drug delivery system for the delivery of antiviral agents

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4898733A (en) * 1985-11-04 1990-02-06 International Minerals & Chemical Corp. Layered, compression molded device for the sustained release of a beneficial agent
US5141752A (en) * 1986-05-09 1992-08-25 Alza Corporation Delayed drug delivery device
US4994273A (en) * 1987-11-02 1991-02-19 Merck & Co., Inc. Solubility modulated drug delivery device
US5098443A (en) * 1989-03-23 1992-03-24 University Of Miami Method of implanting intraocular and intraorbital implantable devices for the controlled release of pharmacological agents
US5378475A (en) * 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
US5773019A (en) * 1995-09-27 1998-06-30 The University Of Kentucky Research Foundation Implantable controlled release device to deliver drugs directly to an internal portion of the body
US5902598A (en) * 1997-08-28 1999-05-11 Control Delivery Systems, Inc. Sustained release drug delivery devices
US6375972B1 (en) * 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof

Also Published As

Publication number Publication date
CN100594899C (zh) 2010-03-24
KR20050123091A (ko) 2005-12-29
CN1756537A (zh) 2006-04-05
US20040175426A1 (en) 2004-09-09
MXPA05007717A (es) 2005-09-30
CA2513884A1 (en) 2004-08-12
WO2004066983A2 (en) 2004-08-12
WO2004066983A3 (en) 2004-11-18
JP2006516621A (ja) 2006-07-06
AU2004207523A1 (en) 2004-08-12
CN1741793A (zh) 2006-03-01
BRPI0406858A (pt) 2006-01-03
EP1592411A2 (en) 2005-11-09
TW200509998A (en) 2005-03-16
CN1741792A (zh) 2006-03-01

Similar Documents

Publication Publication Date Title
AR042920A1 (es) Liberacion controlada de agentes muy solubles
US20200315984A1 (en) Sublingual and buccal film compositions
EP0294993B1 (en) A generic zero order controlled drug delivery system
ES2411179T3 (es) Oblea de buprenorfina para la terapia de sustitución de drogas
KR102141433B1 (ko) 트로스피움을 이용함으로써 방광 배뇨 장애 및 다른 하부 요도관 장애의 치료를 위한 약물 전달 시스템과 방법
JP2023134518A (ja) 透過性増強された医薬組成物
JP2015166361A (ja) 前房内薬剤送達のための徐放性リザーバーインプラント
JP7278223B2 (ja) 生体浸食性薬物送達デバイス
JP2008520547A (ja) 眼部送達のためのポリマー送達処方
CA3022840A1 (en) Enhanced delivery epinephrine compositions
CA2508303A1 (en) Drug delivery system using subconjunctival depot
KR20120059538A (ko) 설하 및 구강 필름 조성물
JP2011093944A (ja) 生体分解性徐放性ドラッグデリバリーシステム
JP2006516621A5 (es)
JP2013523334A (ja) 治療薬を制御放出するための涙点プラグ
NO2012015I1 (no) Dapoxetine i en hver form beskyttet av basis patent nr 330562
JP7431724B2 (ja) 増強された透過を有する医薬組成物
JP2023159150A (ja) 増強された送達のエピネフリン及びプロドラッグ組成物
ES2236551T3 (es) Combinacion de principios activos para el tratamiento medico de toxicomanias.
JP2002525266A5 (es)
KR20070121555A (ko) 활성제 전달용 누점 플러그
Kalachandra et al. Controlled drug release for oral condition by a novel device based on ethylene vinyl acetate (EVA) copolymer
ES2336215T3 (es) Composiciones farmaceuticas de modafinil con liberacion modificada.
US20210145777A1 (en) Modified-release tiopronin compositions, kits and methods for treating cystinuria and related disorders
US20190091281A1 (en) Delivery pharmaceutical compositions including permeation enhancers

Legal Events

Date Code Title Description
FB Suspension of granting procedure